Rakovina Therapeutics Announces 2024 Q2 Financial Results and Provides Corporate Update
August 30, 2024 16:10 ET
|
Rakovina Therapeutics Inc
All dollar amounts reflected in Canadian dollars unless otherwise stated. VANCOUVER, British Columbia, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a...
Crescendo Biologics presents preclinical data on lead clinical candidate CB307 and unveils its first ‘2 in 1’ immune cell engager CB699 at AACR 2024
April 10, 2024 07:00 ET
|
Crescendo Biologics
Crescendo Biologics presents preclinical data on lead clinical candidate CB307 and unveils its first ‘2 in 1’ immune cell engager CB699 at AACR 2024 Preclinical data demonstrate strong rationale for...
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
April 09, 2024 15:34 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies
April 09, 2024 13:15 ET
|
Nurix Therapeutics, Inc.
Presented new case studies demonstrating clinical responses in two patients with B cell malignancies, chronic lymphocytic leukemia (CLL) and primary central nervous system lymphoma (PCNSL), each with...
Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024
April 09, 2024 12:00 ET
|
Imugene Limited
Imugene announced poster presentations featuring its CF33 oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx at the AACR Conference.
Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting
April 09, 2024 12:00 ET
|
Compass Therapeutics
Major Histocompatibility Complex Class I (MHC-I) negative tumors are refractory to immune-oncology therapies, including resistance to checkpoint blockers, due to the loss of the fundamental...
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
April 09, 2024 12:00 ET
|
Immuneering Corporation
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
Theratechnologies présente des données précliniques au congrès 2024 de l’AACR qui met en évidence la polyvalence et la flexibilité de la plateforme technologique d’oncologie SORT1+(MC)
April 08, 2024 16:30 ET
|
Theratechnologies
Les nouveaux conjugués camptothécine-peptide sont bien tolérés et associés à une régression tumorale marquée dans les modèles de xénogreffe de cancer colorectal et de cancer du sein triple...
Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform
April 08, 2024 16:30 ET
|
Theratechnologies
Novel camptothecin-peptide conjugates are well tolerated and associated with significant tumor regression in colorectal cancer and triple-negative breast cancer xenograft modelsSORT1 gene silencing...
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
April 08, 2024 16:05 ET
|
Cardiff Oncology, Inc.
RAS-mutated mCRC – In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor’s ability to adapt to hypoxia resulting in a significant decrease in both tumor...